Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER2-negative breast cancer.

Trial Profile

Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER2-negative breast cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Irinotecan (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms PHENOMENAL
  • Sponsors Medica Scientia Innovation Research
  • Most Recent Events

    • 20 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top